Enzyme-linked Immunosorbent Assay Market Size & Share, by Type (Indirect ELISA, Sandwich ELISA), End User (Hospitals, Pharmaceutical, Research and Academic Institutions) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5526
  • Published Date: May 07, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Enzyme-linked Immunosorbent Assay Market size is predicted to cross USD 27 billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of enzyme-linked immunosorbent assay was over USD 12 billion.

The growth of this sector can be primarily attributed to the increasing incidence of chronic diseases worldwide. Enzyme-linked immunosorbent assay plays a significant role in detecting, monitoring, and treating these health issues resulting in enhanced patient outcomes.  The cases of chronic diseases globally are expected to grow by 57% by the end of 2025 report as per a report by the World Health Organization This escalating health crisis underscores the critical need for advanced diagnostic tools like ELISA in effectively managing and combating these ailments.

The development of enzyme immunoassays by major industry players contributes to the market's expansion. To identify IgA and IgM antibodies against four SARS-CoV-2 antigens, for example, Bio-Rad introduced the Bio-PlexPro Human IgA and IgM SARS-CoV-2 panels in September 2021. The multiplex immunoassay panels aided in the assessment of therapeutic efficacy by the vaccine developers during the development, clinical, and post-marketing phases.

Enzyme-linked Immunosorbent Assay Market overview
Get more information on this report: Request Free Sample PDF

Enzyme-linked Immunosorbent Assay Sector: Growth Drivers and Challenges

Growth Drivers

  • Advancements in technology - The growth of this market can be attributed to escalating technological developments for example automated enzyme-linked immunosorbent assay systems and enhanced detection methods, have notably propelled the accuracy, sensitivity, and efficiency of ELISA assays.

    Automation, in particular, has streamlined workflows, reduced turnaround times, and minimized the risk of errors, making ELISA an attractive choice for researchers and clinical laboratories seeking high-throughput and reliable diagnostic solutions. As laboratories worldwide transition towards more sophisticated and automated systems, the adoption of technologically advanced ELISA platforms is poised to witness a substantial upswing, driving market revenue.
  • Diagnostics and screening programs - The focus on diagnostics and screening programs as a part of public health initiatives has become a significant growth booster for the market.

    Furthermore, healthcare organizations and governments all over the world are promoting the use of screening programs that help in the early detection and appropriate monitoring of diseases such as chronic diseases including diabetes or cancer through diabetes devices, and others. ELISA has the potential to identify particular biomarkers linked with specific conditions that play a crucial role in screening programs.


  • Competition from alternative technologies - Emerging technologies like molecular diagnostics, which have benefits like increased sensitivity and specificity, pose a serious threat to ELISA. As labs and researchers look into alternate diagnostic techniques that could be more appropriate for particular applications, this obstacle could impede market expansion.

    Comparing traditional ELISA procedures by segments to multiplexing technologies, the former are more efficient since they can frequently evaluate many analytes in a single sample concurrently. When thorough profiling is needed, the incapacity to segment multiplex might force researchers to use alternative methods, which could have an impact on ELISA's market share.
  • Limited multiplexing potential is expected to hamper the growth of the market in the upcoming years.
  • High prices associated are foreseen to pose a limitation on the market growth

Enzyme-linked Immunosorbent Assay Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

USD 12 Billion

Forecast Year Market Size (2036)

USD 27 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Enzyme-linked Immunosorbent Assay Segmentation

Type (Indirect ELISA, Sandwich ELISA)

In enzyme-linked immunosorbent assay market, sandwich ELISA segment is likely to account for around 62% share by 2036. Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms foster innovation in biomarker research, thus, Sandwich ELISA, being a cornerstone in this field, benefits from such partnerships.

The shared expertise and resources in collaborative projects contribute to the development and validation of sandwich ELISA assays, further propelling its market growth. A study found that strategic collaborations in the life sciences industry have increased by over 30% in recent years. The growth of the sandwich ELISA segment is further driven by the rising demand for cancer biomarkers, advancements in precision medicine, increasing investment in biomarker research, the clinical emphasis on disease monitoring, growing pharmaceutical research activities, and strategic alliances and collaborations in the life sciences industry.

End User (Hospitals, Pharmaceutical, Research & Academic Institutions)

In terms of end users, the hospital segment is likely to cross a significant share during the studied period. The shift towards personalized medicine involves tailoring medical decisions and interventions based on individual patient characteristics.

Hospitals are increasingly adopting personalized approaches to improve treatment efficacy, leading to the growth of personalized medicine as a paradigm in healthcare that contributes to the continued use of ELISA in hospital settings. The global personalized medicine sales are projected to reach USD 3.2 trillion by 2027, according to a report.

Our in-depth analysis of the global market includes the following segments:


  • Indirect ELISA
  • Sandwich ELISA

          End User

  • Hospitals
  • Pharmaceutical
  • Research & Academic Institutions

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Enzyme-linked Immunosorbent Assay Industry - Regional Synopsis

North American Market Statistics

The enzyme-linked immunosorbent assay market in the North America region is assessed to witness the largest revenue share of 35% during the forecast period. North America is witnessing a rise in the prevalence of chronic diseases, contributing to increased healthcare expenditures and a focus on early detection.

The demand for advanced diagnostic tools like ELISA is fueled by the imperative to address the growing burden of chronic diseases in the region. Based on statistics in 2020, there will be approximately 2,281,658 cases of cancer in the United States overall year 2020. By 2040, the number is predicted to increase to 3,123,452 instances. North America is at the forefront of technological advancements in healthcare, and the IVD sector is no exception.

APAC Market Analysis

Enzyme-linked immunosorbent assay market in the Asia Pacific is assumed to expand notably registering a growth worth 28% during the studied period. Government initiatives aimed at enhancing healthcare access contribute to the growth of the enzyme-linked immunosorbent assay market in the region. As healthcare becomes more accessible to a larger population, the demand for diagnostic tools like ELISA increases.

Government-backed programs focused on preventive healthcare and disease management create a conducive environment for the adoption of advanced diagnostic technologies, further supporting the growth of the ELISA market. Therefore, many countries from the APAC region have introduced programs and initiatives related to healthcare.

Research Nester
Enzyme-linked Immunosorbent Assay Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Enzyme-linked Immunosorbent Assay Landscape

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Neogen Corporation
    • Bio-Rad Laboratories, Inc.
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • BD (Becton, Dickinson and Company)
    • Agilent Technologies, Inc.
    • BioMérieux SA
    • Ortho Clinical Diagnostics

In the News

  • Neogen Corporation declared an innovative Veratox VIP assay for recognizing Cashew, the second test in Neogen's new line of enhanced quantitative ELISA products. 
  • Siemens Healthineers announced that the SARSCoV2 IgG Antibody Test can evaluate neutralizing antibodies, which is the reason behind its receiving CE marking. This test is the better version of its previously launched COVID-19 antibody testing.

Author Credits:  Radhika Pawar

  • Report ID: 5526
  • Published Date: May 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of enzyme-linked immunosorbent assay was over USD 12 billion.

The market size for enzyme-linked immunosorbent assay is projected to cross USD 27 billion by the end of 2036 expanding at a CAGR of 6% during the forecast period i.e., between 2024-2036.

The major players in the market are F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, BD (Becton, Dickinson and Company), Agilent Technologies, Inc., BioMérieux SA, Ortho Clinical Diagnostics, and others.

In terms of type, the sandwich ELISA segment is anticipated to account for the largest market share of 62% during 2024-2036.

The North American enzyme-linked immunosorbent assay sector is poised to hold the highest share of 35% by 2036.
Enzyme-linked Immunosorbent Assay Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying